Following the sale of its Genetics business (completed in H1 2025), Benchmark is positioned as a focused advanced nutrition and health provider for the aquaculture sector. The company is pursuing a delisting from AIM and Euronext Growth Oslo to optimize capital structure, offering shareholders the opportunity to roll equity into the private company with a special dividend.
Cyborg Score Rationale
Benchmark generates strong margins through a focused product portfolio serving a specialized but growing aquaculture market. However, significant headwinds include shareholder dilution (43% loss over five years), restructuring complexity (delisting initiative), and competitive pressure in nutritional and health products for fish farming.
Top Insights
Completed Genetics business divestiture (H1 2025) generated £76m group profit after tax, enabling £87m debt repayment and simplifying operations toward pure-play Advanced Nutrition and Health positioning.
Advanced Nutrition segment generates maximum revenue and serves salmon, shrimp, and marine fish producers with artemia, probiotics, and specialized diets across Norway, Chile, Iceland, and Canada.
Announced delisting from AIM and Euronext Growth Oslo (early 2025) aims to reduce public company compliance costs; shareholders offered private equity rollover with special dividend as alternative to cash exit.
Named Competitors
Skretting — Global aquaculture feed and nutrition supplier
EWOS — Salmon and fish feed supplier
Sea Lice Treatments — Animal health and aquaculture medicine provider
Recent Developments
(H1 2025) Completed sale of Genetics business with £76m profit after tax
(H1 2025) Repaid Green bond, RCF, and hedging instruments totaling ~£87m
(May 2025) Announced plans to delist from AIM and Euronext Growth Oslo; proposed private equity restructuring
Open the full interactive Benchmark Holdings plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.